Magnitude and Frequency of Cytotoxic T-Lymphocyte Responses: Identification of Immunodominant Regions of Human Immunodeficiency Virus Type 1 Subtype C
暂无分享,去创建一个
T. Ndung’u | P. Gilbert | I. Thior | H. Cao | M. Essex | V. Novitsky | M. F. McLane | T. Peter | S. Gaolekwe | N. Rybak | R. Marlink | T. H. Lee | H. Cao | V. Novitsky | P. Gilbert | T. Peter | S. Gaolekwe | N. Rybak | I. Thior | T. Ndung'u | R. Marlink | M. Essex | H. Cao | M. Mclane | T. Lee | Typhoon Lee | M. McLane
[1] F. Graham,et al. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. , 1993, Vaccine.
[2] D. Hone,et al. Vaccination with a Shigella DNA Vaccine Vector Induces Antigen-Specific CD8+ T Cells and Antiviral Protective Immunity , 2001, Journal of Virology.
[3] Y. Okamoto,et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[4] H. Sheppard,et al. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. , 1998, AIDS research and human retroviruses.
[5] Gilcher Ro. Human retroviruses and AIDS. , 1988 .
[6] Neff Walker,et al. Estimated Global Distribution and Regional Spread of HIV‐1 Genetic Subtypes in the Year 2000 , 2002, Journal of acquired immune deficiency syndromes.
[7] P. Kaleebu,et al. Cross‐clade recognition of p55 by cytotoxic T lymphocytes in HIV‐1 infection , 1998, AIDS.
[8] A. McMichael,et al. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. , 1999, Vaccine.
[9] F. Vannberg,et al. Human Immunodeficiency Virus Type 1 Subtype C Molecular Phylogeny: Consensus Sequence for an AIDS Vaccine Design? , 2002, Journal of Virology.
[10] B. Walker,et al. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development , 1997, Journal of virology.
[11] D. Simmons,et al. Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen , 1995, Journal of virology.
[12] B. Moss,et al. Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination , 2001, Journal of Virology.
[13] E. Wherry,et al. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. , 1999, Journal of immunology.
[14] W. Fawzi,et al. Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. , 2001, Journal of human virology.
[15] B. Moss,et al. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[16] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[17] M. Reitz,et al. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. , 2001, Vaccine.
[18] Y. Paterson,et al. Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. , 1999, Journal of immunology.
[19] B. Guy,et al. Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein , 1993, Journal of virology.
[20] E. Rosenberg,et al. Differential Narrow Focusing of Immunodominant Human Immunodeficiency Virus Gag-Specific Cytotoxic T-Lymphocyte Responses in Infected African and Caucasoid Adults and Children , 2000, Journal of Virology.
[21] J. Yewdell,et al. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.
[22] A. McMichael,et al. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. , 2000, Nature Medicine.
[23] N. Shastri,et al. Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. , 1995, Journal of immunology.
[24] B. Graham. Clinical trials of HIV vaccines. , 2002, Annual review of medicine.
[25] Brian T. Foley,et al. HIV Sequence Compendium 2018 , 2010 .
[26] J. Frelinger,et al. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians , 1997, Journal of virology.
[27] S. Rowland-Jones,et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. , 1998, The Journal of clinical investigation.
[28] T. F. Rinke de Wit,et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. , 1999, AIDS.
[29] K. Cease,et al. New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design. , 1999, AIDS.
[30] Steven M. Wolinsky,et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes , 2002, Nature.
[31] T. Ndung’u,et al. Construction and Analysis of an Infectious Human Immunodeficiency Virus Type 1 Subtype C Molecular Clone , 2001, Journal of Virology.
[32] B. Moss,et al. Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus Monkeys , 2001, Journal of Virology.
[33] A. Hughes,et al. Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1). , 1995, Molecular biology and evolution.
[34] J. Blackard,et al. Increased promoter diversity reveals a complex phylogeny of human immunodeficiency virus type 1 subtype C in India. , 2000, Journal of human virology.
[35] B. Moss,et al. Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge , 2000, Journal of Virology.
[36] B. Walker,et al. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. , 2000, The Journal of infectious diseases.
[37] J. Albert,et al. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. , 1999, AIDS research and human retroviruses.
[38] S. Rowland-Jones,et al. Distinct Recognition of Non-Clade B Human Immunodeficiency Virus Type 1 Epitopes by Cytotoxic T Lymphocytes Generated from Donors Infected in Africa , 1999, Journal of Virology.
[39] J. Heeney,et al. AIDS vaccine development in primate models. , 1998, AIDS.
[40] Todd M. Allen,et al. Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen1 , 2000, The Journal of Immunology.
[41] B. Gicquel,et al. Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. , 1997, AIDS research and human retroviruses.
[42] Henryk Mach,et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.
[43] Philip J. R. Goulder,et al. PeptGen: Designing Peptides for Immunological Studies and Application to HIV Consensus Sequences , 2000 .
[44] T. Ndung’u,et al. Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana. , 2000, Virology.
[45] I. M. Belyakov,et al. Rabies Virus-Based Vectors Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Protein Induce a Strong, Cross-Reactive Cytotoxic T-Lymphocyte Response against Envelope Proteins from Different HIV-1 Isolates , 2001, Journal of Virology.
[46] G. Pozzi,et al. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. , 1998, Vaccine.
[47] James G. Herndon,et al. Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine , 2001, Science.
[48] J. Berzofsky,et al. Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein , 1998, Journal of Virology.
[49] Winston A Hide,et al. Conserved domains of subtype C nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. , 2001, AIDS research and human retroviruses.
[50] P. Sharp,et al. A Comprehensive Panel of Near-Full-Length Clones and Reference Sequences for Non-Subtype B Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[51] Alessandro Sette,et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia , 2000, Nature.
[52] A. Simon,et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.
[53] A. Hughes,et al. Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1). , 1998, Molecular biology and evolution.
[54] E. Rosenberg,et al. Rapid Definition of Five Novel HLA-A∗3002-Restricted Human Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Epitopes by Elispot and Intracellular Cytokine Staining Assays , 2001, Journal of Virology.
[55] J. Berzofsky. Immunodominance in T lymphocyte recognition. , 1988, Immunology letters.
[56] J. Carr,et al. Characterization of full-length HIV type 1 subtype C sequences from South Africa. , 2001, AIDS research and human retroviruses.
[57] D. Montefiori,et al. ALVAC-SIV-gag-pol-env-Based Vaccination and Macaque Major Histocompatibility Complex Class I (A*01) Delay Simian Immunodeficiency Virus SIVmac-Induced Immunodeficiency , 2002, Journal of Virology.
[58] R. Zinkernagel,et al. Hierarchies of antigen‐specific cytotoxic T‐cell responses , 1998, Immunological reviews.
[59] C Crimi,et al. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. , 2001, Vaccine.
[60] J. Esparza,et al. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? , 2000, The Lancet.
[61] G. Dougan,et al. Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain of Salmonella. , 1994, Journal of immunology.
[62] R. Young,et al. Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines , 1991, Nature.
[63] P. Flores-Villanueva,et al. Identification of most frequent HLA class I antigen specificities in Botswana: relevance for HIV vaccine design. , 2001, Human immunology.
[64] K. Cease,et al. A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein. , 1999, Vaccine.
[65] Edward C. Holmes,et al. Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.
[66] F. Vannberg,et al. Identification of Human Immunodeficiency Virus Type 1 Subtype C Gag-, Tat-, Rev-, and Nef-Specific Elispot-Based Cytotoxic T-Lymphocyte Responses for AIDS Vaccine Design , 2001 .
[67] J. Mcghee,et al. Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. , 1996, Journal of biotechnology.
[68] M. Robert-Guroff,et al. Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. , 2001, Immunology letters.
[69] E. Rosenberg,et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[70] B. Gicquel,et al. Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice , 1997, Journal of virology.
[71] H. Eisen,et al. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. , 1995, Journal of immunology.
[72] M. L. Clements-Mann,et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. , 1999, The Journal of infectious diseases.
[73] Todd M. Allen,et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef , 1999, Nature Medicine.
[74] J. Lieberman,et al. Induction of Human Immunodeficiency Virus (HIV)-Specific CD8 T-Cell Responses by Listeria monocytogenes and a Hyperattenuated Listeria Strain Engineered To Express HIV Antigens , 2000, Journal of Virology.
[75] J. Morvan,et al. Cross-Reactions between the Cytotoxic T-Lymphocyte Responses of Human Immunodeficiency Virus-Infected African and European Patients , 1998, Journal of Virology.
[76] E. Rosenberg,et al. Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses , 2002, AIDS.
[77] A. García-Sastre,et al. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. , 1999, Vaccine.
[78] B. Gicquel,et al. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. , 1998, AIDS research and human retroviruses.
[79] N. Nathanson,et al. The role of nonhuman primates in the development of an AIDS vaccine. , 1999, AIDS.
[80] P. Earl,et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. , 2002, Vaccine.
[81] M. Johnston,et al. The role of nonhuman primate models in AIDS vaccine development. , 2000, Molecular medicine today.
[82] C. Ho,et al. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. , 1996, Journal of immunology.
[83] D. Gotte,et al. Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. , 1996, AIDS research and human retroviruses.
[84] F. Frankel,et al. Systemic Immunity and Mucosal Immunity Are Induced against Human Immunodeficiency Virus Gag Protein in Mice by a New Hyperattenuated Strain of Listeria monocytogenes , 2001, Journal of Virology.
[85] C. DeLisi,et al. The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design. , 1997, Vaccine.
[86] A. Craiu,et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[87] J. Albert,et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.
[88] J. Levy,et al. Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein , 1995, Journal of virology.
[89] M. Zazzi,et al. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. , 1999, AIDS research and human retroviruses.
[90] D. Robertson,et al. Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. , 2001, AIDS research and human retroviruses.
[91] A. Iwasaki,et al. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. , 1997, Journal of immunology.
[92] M. Hofnung,et al. Induction of T cell responses by chimeric bacterial proteins expressing several copies of a viral T cell epitope , 1993, European journal of immunology.
[93] M. Peeters,et al. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[94] P. Biberfeld,et al. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response , 2001, Gene Therapy.
[95] B. Walker,et al. HIV Molecular Immunology 2001 , 2001 .
[96] F. Vannberg,et al. Molecular Cloning and Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Subtype C: a Set of 23 Full-Length Clones from Botswana , 1999, Journal of Virology.
[97] Forest M. White,et al. Immunodominance Among EBV-Derived Epitopes Restricted by HLA-B27 Does Not Correlate with Epitope Abundance in EBV-Transformed B-Lymphoblastoid Cell Lines1 , 2000, The Journal of Immunology.
[98] E. Rosenberg,et al. Vpr Is Preferentially Targeted by CTL During HIV-1 Infection1 , 2001, The Journal of Immunology.
[99] J. Neilson,et al. Subtypes of Human Immunodeficiency Virus Type 1 and Disease Stage among Women in Nairobi, Kenya , 1999, Journal of Virology.